{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:26:13Z","timestamp":1770729973201,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007162","name":"Guangdong Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2022A1515011265"],"award-info":[{"award-number":["2022A1515011265"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2020A1515010297"],"award-info":[{"award-number":["2020A1515010297"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","award":["2016008"],"award-info":[{"award-number":["2016008"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-024-02408-0","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T17:03:21Z","timestamp":1719421401000},"page":"67-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bromocriptine sensitivity in bromocriptine-induced drug-resistant prolactinomas is restored by inhibiting FGF19\/FGFR4\/PRL"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9088-5890","authenticated-orcid":false,"given":"Z.","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"16","key":"2408_CR1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/jama.2023.5444","volume":"329","author":"NA Tritos","year":"2023","unstructured":"Tritos NA, Miller KK (2023) Diagnosis and management of pituitary adenomas: a review. JAMA 329(16):1386\u20131398","journal-title":"JAMA"},{"issue":"8","key":"2408_CR2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s11604-023-01400-7","volume":"41","author":"T Tsukamoto","year":"2023","unstructured":"Tsukamoto T, Miki Y (2023) Imaging of pituitary tumors: an update with the 5th WHO classifications-part 1. Pituitary neuroendocrine tumor (PitNET)\/pituitary adenoma. Jpn J Radiol 41(8):789\u2013806","journal-title":"Jpn J Radiol"},{"issue":"2","key":"2408_CR3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jama.2020.3744","volume":"325","author":"PP Huynh","year":"2021","unstructured":"Huynh PP, Ishii LE, Ishii M (2021) Prolactinomas. JAMA 325(2):195","journal-title":"JAMA"},{"issue":"12","key":"2408_CR4","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol 19(12):722\u2013740","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2408_CR5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109(1):42\u201350","journal-title":"Neuroendocrinology"},{"issue":"4","key":"2408_CR6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/cancers16040726","volume":"16","author":"YJ Cheng","year":"2024","unstructured":"Cheng YJ, Wang DP, Tang H et al (2024) Alternations of blood pressure following surgical or drug therapy for prolactinomas. Cancers 16(4):726","journal-title":"Cancers"},{"issue":"5","key":"2408_CR7","first-page":"357","volume":"8","author":"M Filopanti","year":"2008","unstructured":"Filopanti M, Barbieri AM, Angioni AR et al (2008) Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharm J 8(5):357\u2013363","journal-title":"Pharm J"},{"issue":"1","key":"2408_CR8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11060-009-0107-y","volume":"99","author":"ZB Wu","year":"2010","unstructured":"Wu ZB, Zheng WM, Su ZP et al (2010) Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. J Neuro oncol 99(1):25\u201332","journal-title":"J Neuro oncol"},{"issue":"3","key":"2408_CR9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1210\/jc.2011-2902","volume":"97","author":"E Peverelli","year":"2012","unstructured":"Peverelli E, Mantovani G, Vitali E et al (2012) Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs. J Clin Endocrinol Metab 97(3):967\u2013977","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2408_CR10","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40618-023-02010-w","volume":"46","author":"N Wu","year":"2023","unstructured":"Wu N, Zhu D, Li J et al (2023) CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma. J Endocrinol Invest 46(8):1573\u20131587","journal-title":"J Endocrinol Invest"},{"key":"2408_CR11","volume":"518","author":"Z Wu","year":"2020","unstructured":"Wu Z, Zheng Y, Xie W et al (2020) The long noncoding RNA-H19\/miRNA-93a\/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists. Mol Cell Endocrinol 518:111033","journal-title":"Mol Cell Endocrinol"},{"issue":"17","key":"2408_CR12","doi-asserted-by":"crossref","first-page":"7961","DOI":"10.1073\/pnas.90.17.7961","volume":"90","author":"C Missale","year":"1993","unstructured":"Missale C, Boroni F, Losa M et al (1993) Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci USA 90(17):7961\u20137965","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2408_CR13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1677\/joe.0.1650475","volume":"165","author":"HE Turner","year":"2000","unstructured":"Turner HE, Nagy Z, Gatter KC et al (2000) Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. J Endocrinol 165(2):475\u2013481","journal-title":"J Endocrinol"},{"issue":"2","key":"2408_CR14","doi-asserted-by":"crossref","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","volume":"106","author":"O Cooper","year":"2021","unstructured":"Cooper O, Bonert VS, Rudnick J et al (2021) EGFR\/ErbB2-targeting lapatinib therapy for aggressive prolactinomas. J Clin Endocrinol Metab 106(2):e917\u2013e925","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2408_CR15","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1210\/clinem\/dgad020","volume":"108","author":"AR de Castro Moreira","year":"2023","unstructured":"de Castro Moreira AR, Trarbach E, Bueno CBF et al (2023) PRL-R variants are not only associated with prolactinomas but also with dopamine agonist resistance. J Clin Endocrinol Metab 108(7):e450\u2013e457","journal-title":"J Clin Endocrinol Metab"},{"key":"2408_CR16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.brainresbull.2019.03.013","volume":"149","author":"B Hu","year":"2019","unstructured":"Hu B, Mao ZG, Du Q et al (2019) miR-93-5p targets Smad7 to regulate the transforming growth factor-\u03b21\/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma. Brain Res Bull 149:21\u201331","journal-title":"Brain Res Bull"},{"issue":"5","key":"2408_CR17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41419-019-1526-0","volume":"10","author":"C Tang","year":"2019","unstructured":"Tang C, Sun R, Wen G et al (2019) Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK\/EGR1 and AKT\/mTOR pathway respectively. Cell Death Dis 10(5):335","journal-title":"Cell Death Dis"},{"issue":"17","key":"2408_CR18","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1242\/dev.124.17.3221","volume":"124","author":"JR McWhirter","year":"1997","unstructured":"McWhirter JR, Goulding M, Weiner JA et al (1997) A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbx1. Development 124(17):3221\u20133232","journal-title":"Development"},{"issue":"1","key":"2408_CR19","first-page":"148","volume":"1444","author":"T Nishimura","year":"1999","unstructured":"Nishimura T, Utsunomiya Y, Hoshikawa M et al (1999) Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochem Biophys Acta 1444(1):148\u2013151","journal-title":"Biochem Biophys Acta"},{"issue":"10","key":"2408_CR20","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1006\/cyto.1999.0485","volume":"11","author":"MH Xie","year":"1999","unstructured":"Xie MH, Holcomb I, Deuel B et al (1999) FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11(10):729\u2013735","journal-title":"Cytokine"},{"key":"2408_CR21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coph.2015.09.014","volume":"25","author":"I Fernandes-Freitas","year":"2015","unstructured":"Fernandes-Freitas I, Owen BM (2015) Metabolic roles of endocrine fibroblast growth factors. Curr Opin Pharmacol 25:30\u201335","journal-title":"Curr Opin Pharmacol"},{"key":"2408_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302613","author":"C Li","year":"2023","unstructured":"Li C, Chen T, Liu J et al (2023) FGF19-induced inflammatory CAF promoted neutrophil extracellular trap formation in the liver metastasis of colorectal cancer. Adv Sci. https:\/\/doi.org\/10.1002\/advs.202302613","journal-title":"Adv Sci"},{"issue":"6","key":"2408_CR23","doi-asserted-by":"crossref","first-page":"e151601","DOI":"10.1172\/JCI151601","volume":"133","author":"L Chia","year":"2023","unstructured":"Chia L, Wang B, Kim JH et al (2023) HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation. J Clin Investig 133(6):e151601","journal-title":"J Clin Investig"},{"issue":"30","key":"2408_CR24","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1038\/s41388-021-01850-1","volume":"40","author":"TL Chen","year":"2021","unstructured":"Chen TL, Liu HD, Liu ZL et al (2021) FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis. Oncogene 40(30):4941\u20134953","journal-title":"Oncogene"},{"issue":"10","key":"2408_CR25","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.7150\/thno.56369","volume":"11","author":"J Wang","year":"2021","unstructured":"Wang J, Zhao H, Zheng L et al (2021) FGF19\/SOCE\/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells. Theranostics 11(10):5045\u20135060","journal-title":"Theranostics"},{"issue":"22","key":"2408_CR26","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1158\/0008-5472.CAN-17-2039","volume":"77","author":"Y Teng","year":"2017","unstructured":"Teng Y, Zhao H, Gao L et al (2017) FGF19 protects hepatocellular carcinoma cells against endoplasmic reticulum stress via activation of FGFR4-GSK3\u03b2-Nrf2 signaling. Can Res 77(22):6215\u20136225","journal-title":"Can Res"},{"issue":"12","key":"2408_CR27","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","volume":"9","author":"RD Kim","year":"2019","unstructured":"Kim RD, Sarker D, Meyer T et al (2019) First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov 9(12):1696\u20131707","journal-title":"Cancer Discov"},{"issue":"1","key":"2408_CR28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/biomedicines6010034","volume":"6","author":"NS Yee","year":"2018","unstructured":"Yee NS (2018) Update in systemic and targeted therapies in gastrointestinal oncology. Biomedicines 6(1):34","journal-title":"Biomedicines"},{"issue":"1","key":"2408_CR29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s10637-023-01335-w","volume":"41","author":"M Zhou","year":"2023","unstructured":"Zhou M, Zhu S, Xu C et al (2023) A phase Ib\/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. Invest New Drugs 41(1):162\u2013167","journal-title":"Invest New Drugs"},{"key":"2408_CR30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbrc.2022.01.067","volume":"595","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhang X, Han R et al (2022) BLU-554, a selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro. Biochem Biophys Res Commun 595:22\u201327","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2408_CR31","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.7150\/thno.82269","volume":"13","author":"XL Chen","year":"2023","unstructured":"Chen XL, Chen J, Feng WB et al (2023) FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC. Theranostics 13(4):1401\u20131418","journal-title":"Theranostics"},{"issue":"1","key":"2408_CR32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","volume":"79","author":"M Xie","year":"2023","unstructured":"Xie M, Lin Z, Ji X et al (2023) FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol 79(1):109\u2013125","journal-title":"J Hepatol"},{"issue":"12","key":"2408_CR33","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.7150\/thno.57659","volume":"11","author":"Q He","year":"2021","unstructured":"He Q, Huang WJ, Liu DF et al (2021) Homeobox B5 promotes metastasis and poor prognosis in hepatocellular carcinoma, via FGFR4 and CXCL1 upregulation. Theranostics 11(12):5759\u20135777","journal-title":"Theranostics"},{"issue":"2","key":"2408_CR34","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.gendis.2023.03.031","volume":"11","author":"X Wang","year":"2024","unstructured":"Wang X, Luo L, Xu J et al (2024) Echinatin inhibits tumor growth and synergizes with chemotherapeutic agents against human bladder cancer cells by activating p38 and suppressing Wnt\/\u03b2-catenin pathways. Genes Dis 11(2):1050\u20131065","journal-title":"Genes Dis"},{"issue":"8","key":"2408_CR35","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/nm.4363","volume":"23","author":"B Benoit","year":"2017","unstructured":"Benoit B, Meugnier E, Castelli M et al (2017) Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice. Nat Med 23(8):990\u2013996","journal-title":"Nat Med"},{"issue":"11","key":"2408_CR36","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.3390\/cancers12113313","volume":"12","author":"N Alijaj","year":"2020","unstructured":"Alijaj N, Moutel S, Gouveia ZL et al (2020) Novel FGFR4-targeting single-domain antibodies for multiple targeted therapies against rhabdomyosarcoma. Cancers 12(11):3313","journal-title":"Cancers"},{"issue":"1","key":"2408_CR37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3892\/ijmm.2020.4784","volume":"47","author":"Z Xiao","year":"2021","unstructured":"Xiao Z, Liang J, Deng Q et al (2021) Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5\/cyclin D1 and STAT5\/Bcl-xL signaling pathways. Int J Mol Med 47(1):113\u2013124","journal-title":"Int J Mol Med"},{"issue":"3","key":"2408_CR38","doi-asserted-by":"crossref","first-page":"E490","DOI":"10.1152\/ajpendo.00166.2002","volume":"283","author":"S Yu","year":"2002","unstructured":"Yu S, Zheng L, Asa SL et al (2002) Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter. Am J Physiol Endocrinol Metab 283(3):E490\u2013E495","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"2408_CR39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41420-023-01543-6","volume":"9","author":"H Chen","year":"2023","unstructured":"Chen H, Li JL, Pi CX et al (2023) FGF19 induces the cell cycle arrest at G2-phase in chondrocytes. Cell Death Discov 9(1):250","journal-title":"Cell Death Discov"},{"issue":"12","key":"2408_CR40","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/1759-7714.12883","volume":"9","author":"Z Xin","year":"2018","unstructured":"Xin Z, Song X, Jiang B et al (2018) Blocking FGFR4 exerts distinct anti-tumorigenic effects in esophageal squamous cell carcinoma. Thorac Cancer 9(12):1687\u20131698","journal-title":"Thorac Cancer"},{"issue":"9","key":"2408_CR41","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","volume":"108","author":"RS Auriemma","year":"2023","unstructured":"Auriemma RS, Pirchio R, Pivonello C et al (2023) Approach to the patient with prolactinoma. J Clin Endocrinol Metab 108(9):2400\u20132423","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2408_CR42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11102-023-01305-8","volume":"26","author":"SA Urwyler","year":"2023","unstructured":"Urwyler SA, Karavitaki N (2023) Refractory lactotroph adenomas. Pituitary 26(3):273\u2013277","journal-title":"Pituitary"},{"issue":"5","key":"2408_CR43","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","volume":"143","author":"E Tomlinson","year":"2002","unstructured":"Tomlinson E, Fu L, John L et al (2002) Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143(5):1741\u20131747","journal-title":"Endocrinology"},{"issue":"13","key":"2408_CR44","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1101\/gad.1083503","volume":"17","author":"JA Holt","year":"2003","unstructured":"Holt JA, Luo G, Billin AN et al (2003) Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17(13):1581\u20131591","journal-title":"Genes Dev"},{"issue":"6","key":"2408_CR45","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1158\/1078-0432.CCR-08-0890","volume":"15","author":"A Roidl","year":"2009","unstructured":"Roidl A, Berger HJ, Kumar S et al (2009) Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 15(6):2058\u20132066","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2408_CR46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13046-016-0478-9","volume":"36","author":"L Gao","year":"2017","unstructured":"Gao L, Wang X, Tang Y et al (2017) FGF19\/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res 36(1):8","journal-title":"J Exp Clin Cancer Res"},{"issue":"13","key":"2408_CR47","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1038\/s41388-018-0591-7","volume":"38","author":"L Gao","year":"2019","unstructured":"Gao L, Lang L, Zhao X et al (2019) FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19\/FGFR4 signaling in head and neck squamous cell carcinoma. Oncogene 38(13):2394\u20132404","journal-title":"Oncogene"},{"key":"2408_CR48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.npep.2015.08.001","volume":"54","author":"H Kanasaki","year":"2015","unstructured":"Kanasaki H, Oride A, Mijiddorj T et al (2015) Role of thyrotropin-releasing hormone in prolactin-producing cell models. Neuropeptides 54:73\u201377","journal-title":"Neuropeptides"},{"issue":"6","key":"2408_CR49","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1530\/EJE-14-0013","volume":"170","author":"D Maiter","year":"2014","unstructured":"Maiter D, Delgrange E (2014) Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol 170(6):R213\u2013R227","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2408_CR50","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11102-019-01003-4","volume":"23","author":"ZY Zhu","year":"2020","unstructured":"Zhu ZY, Cui WW, Zhu DM et al (2020) Common tools for pituitary adenomas research: cell lines and primary cells. Pituitary 23(2):182\u2013188","journal-title":"Pituitary"},{"key":"2408_CR51","doi-asserted-by":"crossref","first-page":"1338345","DOI":"10.3389\/fendo.2024.1338345","volume":"15","author":"L Dzialach","year":"2024","unstructured":"Dzialach L, Sobolewska J, Zak Z et al (2024) Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment. Front Endocrinol 15:1338345","journal-title":"Front Endocrinol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02408-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02408-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02408-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T12:55:51Z","timestamp":1736772951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02408-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["2408"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02408-0","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Medical Ethics Committee of Sun Yat-sen University and performed according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained upon admission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The animal experiment was approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University (ethics approval license: SYSU-IACUC-2023\u2013000946).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}}]}}